Alphabet Inc.

Institutional investor · Portfolio as of Q2 2026

Top Holdings28 positions

Checking export access…
Activity:
SPCX

Space Exploration Technologies Corp.

551.2M$94.2B95.0%$170.86-17.29%
1 qtr
New
Unranked
PL

Planet Labs PBC

35.2M$1.2B1.2%$8.19+64.86%
19 qtrssince 2021-Q4
Unchanged
0
ASTS

AST SpaceMobile, Inc.

8.9M$794.7M0.8%$22.74+63.37%
6 qtrssince 2025-Q1
Unchanged
0
CME

CME Group Inc.

3.5M$769.4M0.8%$292.45+3.97%
2 qtrssince 2026-Q1
Unchanged
0
ARM
ARM
ADR

Arm Holdings plc

2M$695.2M0.7%$53.52+278.34%
12 qtrssince 2023-Q3
Unchanged
0
RVMD

Revolution Medicines, Inc.

2.9M$551.8M0.6%$28.69+576.98%
11 qtrssince 2023-Q4
Decreased
0
FRSH

Freshworks Inc.

16.2M$164M0.2%$18.61-23.96%
19 qtrssince 2021-Q4
Unchanged
0
PBLS

Parabilis Medicines, Inc.

4.9M$134.6M0.1%$27.37+6.87%
1 qtr
New
51
TEM

Tempus AI, Inc.

1.6M$89.9M0.1%$35.00+122.29%
9 qtrssince 2024-Q2
Unchanged
0
GTLB

GitLab Inc.

2.7M$83.2M0.1%$54.98-4.74%
17 qtrssince 2022-Q2
Unchanged
0
PATH

UiPath, Inc.

7M$76.5M0.1%$67.93-80.67%
21 qtrssince 2021-Q2
Unchanged
0
LIFE

Ethos Technologies Inc.

3.6M$65.7M0.1%$11.17+265.98%
2 qtrssince 2026-Q1
Decreased
0
PRME

Prime Medicine, Inc.

16.6M$61.1M0.1%$15.16-69.99%
15 qtrssince 2022-Q4
Unchanged
0
FRVO

Fervo Energy Company

1.8M$51.5M0.1%$29.23-68.11%
1 qtr
New
42
PAYP
PAYP
ADR

PayPay Corporation

3.1M$44.8M0.0%$21.34-31.07%
2 qtrssince 2026-Q1
Unchanged
0
MAZE

Maze Therapeutics, Inc.

1.4M$41.4M0.0%$11.01+192.92%
6 qtrssince 2025-Q1
Unchanged
0
RLAY

Relay Therapeutics, Inc.

1.4M$26.4M0.0%$41.71-58.18%
24 qtrssince 2020-Q3
Decreased
0
BBOT

BridgeBio Oncology Therapeutics, Inc.

2.8M$21.5M0.0%$11.58-79.97%
4 qtrssince 2025-Q3
Unchanged
0
OSCR

Oscar Health, Inc.

481,988$13.7M0.0%$26.88+20.57%
22 qtrssince 2021-Q1
Unchanged
0
BEAM

Beam Therapeutics Inc.

321,604$11M0.0%$18.00+46.28%
26 qtrssince 2020-Q1
Unchanged
0
$99.1B
AUM
28
Positions
Q2 2026
Filing
HI rating · 3.0/5
Quarterly 13F Value Change
Reported 13F value ($B)
Reported 13F values and quarter-over-quarter reported value changes; not investment returns.
QuarterReported value in US dollarsReported value change
2025-Q1$1,577,003,761-8.18041914682%
2025-Q2$2,135,229,73535.3978847613%
2025-Q3$2,408,574,70912.8016657655%
2025-Q4$2,579,790,8977.10861022331%
2026-Q1$4,015,568,78155.6548162748%
2026-Q2$99,082,057,6752367.44765384%
Activity profile
$ moved · Q2'26
New100%Increased0%Decreased0%Exited0%
Composition
Equity vs derivatives
Equity100%Puts0%Calls0%
Holding period
Avg 2.2 years
<1Q11%1-4Q18%1-2Y11%2Y+61%

Alphabet Inc. manages $99.1B across 28 positions as of Q2 2026. Top holdings: SPCX (95.0%), PL (1.2%), ASTS (0.8%). Fund DNA: Concentrated Value. HoldingsIntel Score: 3/5.0.

Q2 2026 Summary

Added SPCX, PBLS and FRVO; exited TNYA; trimmed 4, led by RVMD (−345,906 shares). Top move: PBLS (NEW, conviction 51). Portfolio: $99.1B across 28 positions.

Top holdings by portfolio weight

Total AUM$99B
SPCX95.05%
PL1.18%
ASTS0.80%
CME0.78%
ARM0.70%
RVMD0.56%
FRSH0.17%
PBLS0.14%
TEM0.09%
GTLB0.08%
Other0.08%

Portfolio allocation by GICS sector

Sectors4
Technology38.88%
Industrials24.98%
Healthcare18.28%
Financial Services17.86%

Behavioral investing profile

Checking access…
Concentrated Value
Compare DNA across all funds
7-dimension, SEC 13F-derived research score
Solid(3.0 / 5.0)
Holdings P&L45
Conviction71
Concentration100
Checking access…

Position Outcomes

Best and worst performing positions by estimated return

Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.

Similar Funds

Funds with similar investing DNA

Accumulation Streaks

Positions with 2+ consecutive quarters of increases - persistent directional conviction.

No active accumulation streaks detected for this filer.

Streaks require 2+ consecutive quarters of increased positions in the most recent period.

Famous Investors' Portfolios

What the most-followed managers hold, and what they bought and sold each quarter.

Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer

Verify source filings on SEC EDGAR

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used